Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. filed an initial ownership report for director Craig Wichner. The Form 3 indicates that, as of the event date of 11/05/2025, he beneficially owns 0 shares of Cibus Class A Common Stock in direct form. The filing also shows no reportable derivative securities, meaning there are no listed options, warrants, or other convertible instruments tied to Cibus stock for this reporting person at this time.
Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.
Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.
Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.
Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.
Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.
Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.
Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.
Cibus, Inc. (CBUS) Form 3 filed by Kimberly A. Box discloses her role as a director and reports zero shares of Class A common stock and no derivative securities as of the 09/11/2025 event date. The filing is an initial beneficial-ownership statement and was signed by an attorney-in-fact on 09/26/2025. The disclosure documents the absence of direct equity holdings by this reporting director.
Cibus, Inc. disclosed an Executive Employment Agreement appointing Cornelis (Carlo) Broos as Chief Financial Officer effective September 18, 2025 (agreement dated September 19, 2025). The agreement is at-will but provides severance protections: 18 months of continued base salary if the company terminates him without Cause or he leaves for Good Reason; and enhanced 24-month severance plus a lump-sum bonus equal to his target annual bonus (or a projected portion if termination occurs in the second half of the fiscal year) and full vesting of unvested equity if termination happens in connection with a Change in Control. Severance payments require customary release delivery. For tax efficiency, about half of Mr. Broos’ compensation will be paid to a Belgian entity wholly owned by him. The filing notes no family relationships or other arrangements related to the appointment.
Cibus, Inc. notified the appointment and compensation terms for non-employee director Ms. Box. The Board adopted a Non-Employee Director Compensation Policy providing Ms. Box an annual cash retainer of $60,000 payable semi-annually and equity compensation with a grant-date value of $90,000 to be issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended. The award will be prorated to reflect Ms. Box's service for the remainder of the 2025 fiscal year. The filing is signed by Peter Beetham, Ph.D., Interim Chief Executive Officer.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,540,536 shares of Cibus, Inc. Class A common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises shared voting and dispositive power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported to share voting and dispositive power. The Master Fund disclaims direct beneficial ownership by reason of the management agreement. The filing states the holdings are owned in the ordinary course of business and not for the purpose of changing or influencing control.
Cibus, Inc. reported continued losses and liquidity pressure while narrowing its operational focus to commercialize rice herbicide-tolerance traits. The company recorded a $76.0 million net loss for the six months ended June 30, 2025, and used $25.4 million of cash in operating activities during that period. Cash and cash equivalents were $36.5 million versus current liabilities of $22.4 million, and an accumulated deficit of $803.4 million. Management expects to continue incurring losses and needs additional capital within a year; this raises substantial doubt about the companys ability to continue as a going concern. Cibus implemented cost reductions and a restructuring, targets annual net cash usage of approximately $30.0 million by 2026, and is prioritizing Rice weed-management traits that it estimates could represent >$200 million of annual accessible royalties upon full commercialization. The company recognized a $21.0 million goodwill impairment in Q1 2025 and completed equity transactions in Jan and Jun 2025 to raise net proceeds of about $46.4 million combined.